[MO31] Mini-Oral Session 31　臨床試験推進プログラム1（Trial in Progress）

[MO31-3] Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): A Phase 2 Study (DESTINY-Lung02)

^○後藤 功一¹, F. Smit Egbert², T. Li Bob³, Mazieres Julian⁴, Planchard David⁵, 中川 和彦⁶, Paz-Ares Luis⁷, Novello Silvia⁸, Yang James Chih-Hsin⁹, Ahn Myung-Ju¹⁰, Liu Geoffrey¹¹, O’Byrne Kenneth¹², Aregay Mehreteab¹³, 志賀 遼太¹³, Saxena Kapil¹³, Pereira Kaline¹³, Meinhardt Gerold¹³, A. Janne Pasi¹⁴ (1.国立がん研究センター東病院, 2.Netherlands Cancer Institute, Amsterdam, Netherlands, 3.Memorial Sloan Kettering Cancer Center, New York, NY, USA, 4.Institut Universitaire du Cancer, Toulouse, France, 5.Gustave Roussy, Villejuif, France, 6.近畿大学病院, 7.Hospital Universitario 12 de Octubre, Madrid, Spain, 8.University of Turin, AOU San Luigi-Orbassano (TO), Orbassano, Italy, 9.National Taiwan University Cancer Center, Taipei, Taiwan, 10.Samsung Medical Center, Seoul, South Korea, 11.Princess Margaret Cancer Centre, Toronto, ON, Canada, 12.Princess Alexandra Hospital, Brisbane, QLD, Australia, 13.Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 14.Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, USA)